Moderna Inc. said Thursday a Phase 3 trial of its next-generation COVID-19 vaccine met its main goal and showed higher ...

The FDA has approved new versions of Pfizer/BioNTech's Comirnaty and Moderna's Spikevax COVID-19 vaccines that target the Omicron KP.2 strain of SARS-CoV-2 which was dominant in the US in recent ...

In a press release issued in Denmark by the Danish Medicines Agency, media have been informed that a side effect of taking Moderna's COVID vaccine, also known as Spikevax, may result in chronic hives.

According to the lawsuit, the development of Moderna’s COVID-19 vaccine, Spikevax, depended on key technological advancements made at Northwestern. Also Read: Alnylam’s Concedes Its Patent ...

Shares up nearly 5% to $54.22 in early trading Spikevax COVID vaccine sales reached $1.8 billion, beating expectations Moderna expects lower COVID vaccine sales this year compared to 2023 $10 ...

The lawsuits specifically concern Moderna’s COVID-19 vaccine, Spikevax, and its more recently approved mRNA shot for respiratory syncytial virus (RSV), mRESVIA. GSK claims Moderna is marketing ...

The lawsuit said, opens new tab Moderna uses Northwestern-developed lipid nanoparticle (LNP) technology without a license in Spikevax shots to transport fragile messenger RNA into the human body.

The Massachusetts-based company said that third-quarter revenue from its Spikevax shot came in at $1.8 billion, with $1.2 billion of the sales coming in the United States. The overall figure ...

According to GSK, the technology used in Moderna’s vaccines, including its Spikevax family of vaccines, is based on a platform created by the team led by vaccinologist Christian Mandl.

According to Reuters, the company earned $6.7 billion in revenue from Spikevax in 2023. Moderna has stated in the past that it is “not aware of any significant intellectual property impediments ...

Moderna earned $6.7 billion in revenue from Spikevax last year. Pfizer made $11.2 billion from sales of Comirnaty, the COVID vaccine it developed with German partner BioNTech. Sales of both ...

Overcast and grey today with little in the way of any brightness in the morning. Later in the day, some brighter breaks are more likely but only locally and briefly. Some drizzle is also possible ...